Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol (Q80036912)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

28 December 2019

title

Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

Mott JH

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

28 December 2019

Livsey JE

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

28 December 2019

Logue JP

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

English

0 references

publication date

1 May 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

British Journal of Radiology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

28 December 2019

volume

77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

28 December 2019

issue

917

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

377-386

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Fractionation and protraction for radiotherapy of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Toward optimal external-beam fractionation for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Is alpha/beta for prostate tumors really low?

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Is the alpha/beta ratio for prostate cancer low?

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

How low is the alpha/beta ratio for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Hypofractionation for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Retrospective study of radiotherapy in early carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Scoring of treatment-related late effects in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Number and orientations of beams in intensity-modulated radiation treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1259/BJR/66104316

21 January 2018

Identifiers

DOI

10.1259/BJR/66104316

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121701 AND SRC:MED&resulttype=core&format=json

28 December 2019

1 reference